Clinical Trial Update: A Study of Paliperidone Palmitate 6-Month Formulation [Phase 3]

View source ↗

Summary

Phase 3 trial of paliperidone palmitate 6-month formulation for schizophrenia has been completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Paliperidone palmitate 6-month formulation (paliperidone palmitate)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2021-12-09